Efficacy and safety of hyperbaric oxygen therapy for moderate-to-severe ulcerative colitis: a protocol for a systematic review and meta-analysis

Abstract

IntroductionUlcerative colitis (UC) is a type of inflammatory bowel disease, and 62% of patients with UC felt that it is difficult for them to live a normal life. Furthermore, some researches have shown that about 15% of patients with UC undergo at least one extreme clinical course in their lifetime, and 10%–30% of patients with UC oblige colectomy. Although many investigations have demonstrated that HBO2 has a beneficial impact on UC treatment, a systematic review and meta-analysis are unavailable. Therefore, a meta-analysis is essential to assess the efficacy and safety of HBO2 in treating UC.Methods and analysisA systematic search plan will be performed in the following seven databases with a restriction of time from inception to September 2020 to filter the eligible studies: PubMed, Web of Science, Embase, Cochrane Library, China National Knowledge Infrastructure, Chinese Scientific Journal Database (VIP) and Chinese Biomedical Database WanFang. Other related resources will be also searched. Two independent reviewers will choose eligible researches and extract data. The risk of bias will be evaluated based on Cochrane Collaboration’s Risk of Bias tool and Newcastle-Ottawa Scale. Eventually, a systematic review and meta-analysis will be performed via the Review Manager V.5.3 statistical software and STATA V.14.0 software.Ethics and disseminationThis study will not involve the individual patient and any ethical problems since its outcomes are based on published data. Therefore, no ethical review and approval are required. We plan to publish the study in a peer-reviewed journal.PROSPERO registration numberCRD42020210244.

Retracted: Design, development, and evaluation of a registry system for hyperbaric oxygen therapy: A methodological study

“…14 Based on all the biochemical effects mentioned above, HBOT has been proven to be safe and effective either alone or as an adjunct method in treating various diseases, with few side effects. 15,16 According to the Undersea and Hyperbaric Medicine Society (UHMS), HBOT is approved for the following indications; carbon monoxide poisoning, crushing traumas, compartment syndrome, cyanide intoxication, gas gangrene, decompression sickness, compromised skin graft, central retinal artery occlusion, osteomyelitis, delayed radiation injury, necrotizing soft tissue infection, air or gas embolism, actinomycosis, acute thermal burns, sensorineural hearing loss, anemia, and diabetic wounds. 15 Possible adverse effects of HBOT are as follows: barotraumatic middle ear injury, sinus damage, oxygen poisoning-which can cause pulmonary failure, pulmonary fluid congestion, seizures or myopia-claustrophobia, hypoglycemia in diabetics, dizziness, and weakness.…”

“…15,16 According to the Undersea and Hyperbaric Medicine Society (UHMS), HBOT is approved for the following indications; carbon monoxide poisoning, crushing traumas, compartment syndrome, cyanide intoxication, gas gangrene, decompression sickness, compromised skin graft, central retinal artery occlusion, osteomyelitis, delayed radiation injury, necrotizing soft tissue infection, air or gas embolism, actinomycosis, acute thermal burns, sensorineural hearing loss, anemia, and diabetic wounds. 15 Possible adverse effects of HBOT are as follows: barotraumatic middle ear injury, sinus damage, oxygen poisoning-which can cause pulmonary failure, pulmonary fluid congestion, seizures or myopia-claustrophobia, hypoglycemia in diabetics, dizziness, and weakness. 17,18 Although, despite all the aforementioned therapeutic effects of HBOT, most of the available evidence regarding its efficiency is based on small-scale randomized clinical trials (RCTs), and retrospective studies.…”

Hyperbaric oxygen therapy ameliorates intestinal and systematic inflammation by modulating dysbiosis of the gut microbiota in Crohn’s disease

“…HBOT can enhance healing in ischemic colonic anastomosis by improving the local anaerobic environment [ 12 ]. Similarly, a few case reports have indicated that HBOT can improve clinical manifestations of IBD, although the underlying mechanisms have not been explored [ 13 , 14 ]. Based on these findings, we hypothesize that HBOT will benefit patients with CD by modulating the composition of the host gut microbiota, thereby influencing the efficacy of biologic agents.…”